Last updated: February 24, 2026
What Is NDC 45802-0736?
The National Drug Code (NDC) 45802-0736 corresponds to Carfilzomib (brand name Kyprolis), an FDA-approved proteasome inhibitor used to treat multiple myeloma. It is marketed by Amgen Inc. Since its approval in 2012, Kyprolis has established itself as a key drug in the relapsed or refractory multiple myeloma treatment landscape.
Market Landscape Overview
Market Size and Growth
The multiple myeloma drug market has experienced steady growth. In 2022, the global multiple myeloma therapeutics market size was valued at approximately $10.2 billion and is projected to grow at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2030 (Fortune Business Insights, 2023).
Kyprolis accounts for a significant share of this market, though competition from drugs such as Darzalex (daratumumab) and Pomalyst (pomalidomide) reduces its market dominance.
Market Penetration
Kyprolis is indicated for use in various lineings of therapy, including as a monotherapy and in combination regimens. It is administered intravenously, which introduces considerations for healthcare provider logistics and patient compliance.
Key Competitors
| Drug |
Mechanism |
Indication |
Market Share (2022) |
Price Range (per cycle) |
| Carfilzomib |
Proteasome inhibitor |
Multiple myeloma |
20-25% |
$11,000 - $14,000 |
| Daratumumab |
Monoclonal antibody |
Multiple myeloma |
40-45% |
$34,000 - $45,000 per 28-day cycle |
| Pomalidomide |
Immunomodulator |
Multiple myeloma refractory |
15-20% |
$15,000 - $20,000 per cycle |
(Note: Exact market share varies geographically and via payor policies.)
Price Trends & Projections
Historical Price Data
Kyprolis's wholesale acquisition costs (WAC) have remained relatively stable over recent years:
| Year |
Average WAC per cycle |
Comments |
| 2020 |
~$11,500 |
Stable amid competition |
| 2022 |
~$12,000 |
Slight increase |
Factors Influencing Price Movements
- Market Competition: Introduction of biosimilars or alternative therapies could drive prices lower.
- Regulatory Changes: Price control policies or rebate reforms may impact net prices.
- Product Innovation: New formulations or combinations could carry premium pricing.
Future Price Projections (2023-2030)
Based on current trends, an annual escalation of 2-3% appears plausible absent new competition:
| Year |
Estimated Price Range / Cycle |
Assumption |
| 2023 |
$12,200 - $12,600 |
Continuation of recent trend |
| 2025 |
$13,000 - $13,500 |
Potential slight increase |
| 2030 |
$14,400 - $15,000 |
Cumulative growth over 7 years |
Summary of Price Drivers
- Negotiated rebates: In commercial contracts, net prices may be substantially lower than WAC.
- Market uptake: Greater adoption in line-ups could temper price growth due to supplier competition.
- Value-based pricing: New clinical data and comparator efficacy could justify higher or lower list prices.
Key Market Drivers & Challenges
- Growing multiple myeloma prevalence
- Expanding label indications: New combination approvals can increase utilization.
- Price sensitivity: Payers strictly evaluate costly therapies; rebates and formulary placements influence actual net prices.
- Patent exclusivity: Patent expiration, expected around 2027, risks generic biosimilar entry, pressuring prices.
Regulatory & Policy Context
- Medicare & Medicaid Price Negotiation: The Inflation Reduction Act of 2022 authorizes negotiation for selected drugs; impacts high-cost drugs like Kyprolis.
- Biosimilar development: Biosimilars for proteasome inhibitors are under development, targeting price reductions.
Summary
| Aspect |
Insights |
| Market Size |
$10.2 billion globally (2022); CAGR 8.5% through 2030 |
| Revenue Drivers |
Growing multiple myeloma cases, expanded indications |
| Price Trends |
Stable recent years; projected 2-3% annual increase |
| Competitive Risks |
Biosimilar entry, payer negotiations, policy reforms |
| Pricing Strategies |
Mix of list price, rebates, and negotiations affects net revenue |
Key Takeaways
- NDC 45802-0736 (Kyprolis) commands a current WAC of around $12,000 per cycle.
- The drug's market is expanding but faces competition from other therapies and biosimilars.
- Price projections suggest modest growth, contingent upon market dynamics and regulatory developments.
- The expiration of patent protection and biosimilar proliferation could reduce prices significantly post-2027.
- Payer negotiations and policy changes will influence actual net prices more than list prices.
FAQs
1. What is the expected timeline for biosimilar entry for Kyprolis?
Biosimilar development is underway, with tentative FDA filings anticipated around 2025-2026; actual market entry depends on regulatory approval and market strategies.
2. How does the cost of Kyprolis compare to competing agents?
Kyprolis's cost per cycle is approximately $12,000, lower than Daratumumab's $34,000-$45,000, but with a different administration profile and efficacy profile influencing choice.
3. Will future policies limit drug prices for proteasome inhibitors?
Potentially. Legislation like the Inflation Reduction Act grants authorities the power to negotiate prices for certain high-cost drugs, including cancer therapies.
4. How do formulary placements affect Kyprolis's pricing and utilization?
Formulary inclusion and tier placement impact access and rebates, influencing the net price paid by payers and hospitals.
5. What clinical developments could influence Kyprolis's market position?
New combination therapies demonstrating superior efficacy or fewer side effects could shift prescribing patterns, affecting market share and pricing.
References
[1] Fortune Business Insights. (2023). Global Multiple Myeloma Therapeutics Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com.
[2] FDA. (2012). Kyprolis (Carfilzomib) approval information. U.S. Food and Drug Administration.
[3] IQVIA. (2022). Healthcare Market Insights. IQVIA Institute for Human Data Science.
